Dr. Zhanhong Chen 陈占红
Chief Physician
Department of Medical Oncology (Breast Cancer), Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of mastitis, breast hyperplasia, breast nodules, and breast cancer. Postoperative adjuvant therapy for breast cancer.
Dr. Chen holds a bachelor’s degree from Zhejiang University School of Medicine (1999) and a master’s in integrative oncology from Zhejiang Chinese Medical University (2008). With over ten years in medical oncology, Dr. Chen focuses on comprehensive treatment of breast cancer, lung cancer, gastrointestinal tumors, osteosarcoma, and lymphoma. Dr. Chen has participated in more than 20 multicenter clinical trials.
Professional roles
- Secretary, Medical Cell Biology Professional Committee, Zhejiang Society for Cell Biology
- Member, Tumor Immunology and Biotherapy Professional Committee, Zhejiang Immunological Society
Name order: in Chinese the family name comes first (Chen Zhanhong). Papers usually list the name as Zhanhong Chen or Chen Z.
Selected publications
42 papers on PubMed matched by name and affiliation; 10 as first or senior author since 2016. Most recent first- or senior-author papers:
- Transl Breast Cancer Res, 2023 (senior author): Individualize management for advanced breast cancer with pyrotinib-based anti-HER2 therapy: a case report. PubMed 38751473
- Front Pharmacol, 2022 (senior author): Cardiac Safety in Breast Cancer Patients Receiving Pegylated Liposome Doxorubicin Sequential Anti-HER2 Monoclonal Antibody Therapy. PubMed 35991878
- Front Oncol, 2022 (first author): Real-World First-Line Treatment Patterns and Outcomes in Hormone Receptor-Positive Advanced Breast Cancer Patients: A Multicenter, Retrospective Study in China. PubMed 35311126
- Front Cell Dev Biol, 2021 (senior author): ADAMTS9-AS1 Constrains Breast Cancer Cell Invasion and Proliferation via Sequestering miR-301b-3p. PubMed 34900984
- Ann Transl Med, 2021 (senior author): Exploring the concepts and practices of advanced breast cancer treatment: a narrative review. PubMed 33987419
- Medicine (Baltimore), 2020 (senior author): Efficacy of fulvestrant 500 mg in Chinese postmenopausal women with advanced/recurrent breast cancer and factors associated with prolonged time-to-treatment failure: A retrospective case series. PubMed 32702824
- Mol Genet Genomic Med, 2020 (first author): Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling. PubMed 31867841
- Cancer Med, 2019 (first author): Everolimus-containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study. PubMed 31385461
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion